BSPM:OTC-Biostar Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 0.07

Change

0.00 (0.00)%

Market Cap

USD 0.32M

Volume

1.00K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.04 (+0.14%)

USD63.83B 37.72 17.60
MKGAF MERCK Kommanditgesellschaft au..

+4.50 (+3.15%)

USD61.98B 37.74 17.60
TKPHF Takeda Pharmaceutical Company ..

+1.22 (+3.34%)

USD57.55B 51.33 0.13
ESALY Eisai Co., Ltd

+1.75 (+1.94%)

USD25.68B 21.76 0.14
ESALF Eisai Co., Ltd

N/A

USD25.66B 21.85 0.14
SFOSF Shanghai Fosun Pharmaceutical ..

-0.02 (-0.36%)

USD17.25B 20.84 2.64
SGIOF Shionogi & Co., Ltd

-0.87 (-1.58%)

USD16.38B 15.12 0.08
SGIOY Shionogi & Co., Ltd

+0.29 (+2.12%)

USD16.32B 15.22 0.08
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
TEVJF Teva Pharmaceutical Industries..

N/A

USD9.49B 904.00 16.09

ETFs Containing BSPM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.67% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.67% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -56.25% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.25% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -98.57% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.57% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -36.03% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.03% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.72% N/A N/A N/A N/A
Risk Adjusted Return -71.04% N/A N/A N/A N/A
Market Capitalization 0.32M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.18 N/A N/A N/A N/A
Price/Book Ratio 0.01 N/A N/A N/A N/A
Price / Cash Flow Ratio 0.06 N/A N/A N/A N/A
EV/EBITDA 0.06 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 2.66% N/A N/A N/A N/A
Return on Invested Capital -14.90% N/A N/A N/A N/A
Return on Assets 4.25% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.00 N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.51 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike